儿童新诊断免疫性血小板减少症临床管理质量改进倡议的成本效果
该研究从机构视角对鼓励医生在适当情况下对儿童新诊断免疫性血小板减少症(ITP)采用观察而非积极治疗的循证方案进行概率成本效果分析,基于决策树模型和1年时间 horizon,比较方案实施前(2007-2009)与实施后(2013-2018)的患儿数据。结果显示实施后每名患儿平均节省2055加元(95%CI:656,3890加元),且ITP缓解比例更高,在99.7%的模型迭代中该策略成本更低且更有效。
要点
- 实施鼓励观察的循证方案后,每名ITP患儿平均节省2055加元(95%CI:656,3890加元)。
- 方案实施后ITP缓解病例比例更高,且99.7%的模型迭代中策略成本更低且更有效。
- 成本节省已计入质量改进准备和医生培训相关成本。
核心结论
- 实施鼓励适当观察而非积极治疗的循证机构方案,可在每例基础上显著节省成本,即使计入培训相关成本。
研究设计与样本
- 从机构视角进行的概率成本效果分析,使用决策树模型,时间跨度为1年。
主要发现
- 方案实施后每名患儿平均节省2055加元(95%CI:656,3890加元)。
- 方案实施后ITP缓解病例比例更高。
- 在99.7%的模型迭代中,实施策略成本更低且更有效。
关键数值与推荐
- ITP缓解定义为诊断后9-12个月达到持续血小板计数>100×10^3/μL。
临床怎么用
- 在儿童新诊断ITP管理中,可推广鼓励适当观察的循证机构方案以降低医疗成本。
局限性
- 干预的长期成本可持续性尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of an evidence-informed institutional protocol for physicians that encouraged management of children with newly diagnosed immune thrombocytopenia (ITP) with observation over active therapy, where appropriate. STUDY DESIGN: We conducted a probabilistic cost-effectiveness analysis from an institutional perspective using a decision tree with a 1 year time horizon. Patient-level data were retrospectively ascertained for children diagnosed in pre-protocol (2007-2009) and post-protocol (2013-2018) time periods. ITP resolution was defined as achieving a sustained platelet count of >100 × 103/μL at 9-12 months after diagnosis. Outpatient care and inpatient costs were obtained from the institution and provincial sources. Intervention costs accounted for quality improvement initiative preparation and staff physician training. Incremental costs, incremental effects, and CIs were calculated from 10 000 model iterations. RESULTS: Forty-eight patients were followed for 1 year in the pre-protocol period and 84 in the post-protocol period. After protocol implementation, an average cost savings per child managed of $2055 (95% CI: $656, $3890) Canadian Dollars was observed, as was a higher proportion of resolved ITP cases. The implementation strategy remained less costly and more effective in 99.7% of model iterations. CONCLUSIONS: Implementation of an evidence-informed institutional protocol to guide physicians toward increased uptake of observation over active therapy when managing children with newly diagnosed ITP resulted in significant cost savings on a per case basis, even after accounting for training-related costs. Though the long-term cost implications regarding the sustainability of the intervention are not yet known, it is anticipated that continued institutional savings could occur.
引用
- Moskalewicz A, Beck CE, Parkin PC, et al. Cost-Effectiveness of a Quality Improvement Initiative for the Clinical Management of Children with Newly Diagnosed Immune Thrombocytopenia. J Pediatr. 2022. PMID: 36470460. doi:10.1016/j.jpeds.2022.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。